Donnerstag, 9. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Met Non Small Cell Cancer Registry (MOMENT)

Rekrutierend

NCT-Nummer:
NCT05376891

Studienbeginn:
Oktober 2022

Letztes Update:
20.02.2024

Wirkstoff:
-

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
EMD Serono Research & Development Institute, Inc.

Collaborator:
Merck KGaA, Darmstadt, Germany

Studienleiter

Medical Responsible
Study Director
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Kontakt

Studienlocations
(3 von 64)

University Hospital of Tampere
Tampere
FinlandNoch nicht rekrutierend» Google-Maps
Turun Yliopistollinen Keskussairaala
Turku
FinlandNoch nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

This is a disease registry, which is an organized system using non-interventional methods to

collect data on a patient population defined by a particular disease, exposure, or condition,

and which is followed over time. Non-interventional means that after participants enrollment,

participants will be treated according to the routine clinical treatment decision by the

physician. The registry will not impose any treatment or procedure for participants.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Participants who signed ICF

- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and

Confirmed METex14 skipping alterations (by valid assay)

- Participants who are starting or are already being treated with systemic therapy

Exclusion Criteria:

- Participants who are enrolled in a clinical trial

Studien-Rationale

Primary outcome:

1. Best Overall Response (BOR) (Time Frame - Through study completion, up to approximately 4.9 years)

2. Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 (Time Frame - Up to approximately 4.9 years)

3. Overall Survival (OS) (Time Frame - Through study completion, up to approximately 4.9 years)

4. Number of Participants with Adverse Events (AEs) (Time Frame - Up to approximately 4.9 years)

5. Number of Participants with Adverse Reactions (ARs) (Time Frame - Up to approximately 4.9 years)

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Met Non Small Cell Cancer Registry (MOMENT)"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.